SCHEDULE: Tenon Medical Acquires SiVantage & SIMPL Assets

Tenon Medical, Inc. completed the acquisition of SiVantage Inc.'s SImmetry business and SIMPL Medical, LLC's SIMPL business, expanding its sacropelvic fixation and fusion product lines.

Summary

• Tenon Medical, Inc. acquired substantially all assets of SiVantage Inc. (SImmetry Business) and SIMPL Medical, LLC (SIMPL Business) on August 1, 2025.
• The SImmetry Acquisition involved a purchase price of $750,000 cash, 710,300 shares of Tenon Medical Common Stock (with 473,533 held in escrow for indemnification), a royalty on SI Product sales (15% for 1 year, then 10% for 4 years, capped at $5.0 million), and a deferred cash payment up to $1.3 million tied to warrant exercises.
• Tenon Medical may issue up to an additional 867,356 Common Stock shares to SiVantage based on SI Product sales milestones ($1 million, $10 million, $20 million in aggregate sales).
• The SIMPL Acquisition involved a royalty of 30% of net revenue from SIMPL Products for five years after first commercial sale, reducing to 20% if aggregate royalties exceed $20.0 million, with an option for Tenon Medical to pay a percentage of quarterly royalties in Common Stock.
• SiVantage Inc. now beneficially owns 986,528 shares of Tenon Medical Common Stock, representing 12.5% of outstanding shares.
• Wyatt D. Geist and Nathaniel A. Grawey, key personnel from SiVantage and SIMPL, were appointed Chief Innovation Officer and Chief Commercial Officer, respectively, at Tenon Medical, each receiving 138,114 shares of Common Stock.

Sentiment

Score: 7

Explanation: The acquisition expands Tenon Medical's product portfolio and integrates key personnel, which are positive strategic moves. However, the potential for significant share dilution and future cash outflows for royalties and deferred payments introduce some financial considerations.

Positives

• Expansion of Tenon Medical's product portfolio in sacropelvic fixation and fusion with established systems (SImmetry, SImmetry+, SIMPL Products).
• Integration of key personnel (Wyatt D. Geist as Chief Innovation Officer, Nathaniel A. Grawey as Chief Commercial Officer) brings specialized expertise and continuity.
• Royalty-based acquisition structure for SIMPL Business aligns the seller's interest with future sales performance.
• Earnout structure for SImmetry Business incentivizes growth and ties additional share issuance to specific revenue milestones.

Negatives

• Potential for significant share dilution from the initial 710,300 shares, potential 867,356 earnout shares, and potential stock payments for SIMPL royalties.
• Future cash outflows for royalties (capped at $5.0 million for SImmetry, uncapped for SIMPL but with a step-down) and a deferred cash payment.
• 473,533 shares are held in escrow for indemnification claims, indicating potential future liabilities or disputes.

Risks

• Achievement of revenue milestones for earnout shares is not guaranteed and depends on successful commercialization.
• The success of acquired product lines (SI Products, SIMPL Products) is subject to market acceptance, competitive landscape, and effective commercialization efforts.
• Potential for indemnification claims against SiVantage Inc. could affect the escrowed shares.
• Reliance on key personnel (Wyatt D. Geist, Nathaniel A. Grawey) for continued innovation and commercial success post-acquisition.
• Dilution risk from future share issuances for earnouts and potential royalty payments in stock could impact existing shareholder value.

Future Outlook

Tenon Medical anticipates future revenue growth from the acquired SI Products, with potential additional share issuances to SiVantage Inc. upon achieving aggregate sales milestones of $1 million, $10 million, and $20 million within three years. The company also expects to generate revenue from SIMPL Products, with royalty payments to SIMPL Medical, LLC for five years post-commercial sale.

Industry Context

This acquisition signifies Tenon Medical's strategic expansion within the sacropelvic fixation and fusion market, a specialized segment of the broader orthopedic and spine surgery device industry. By acquiring established product lines like SImmetry and SIMPL, Tenon Medical aims to consolidate its position and leverage existing intellectual property and market presence, potentially competing more effectively with larger players in the spine and orthopedic device space.

Management Changes

Legal Proceedings

• The Reporting Person and its Related Persons have not been convicted in criminal proceedings (excluding traffic violations) or been party to civil proceedings resulting in judgments, decrees, or final orders related to federal or state securities laws in the last five years.

Related Party Transactions

• SiVantage Inc. (Reporting Person) sold its SImmetry Business to Tenon Medical, Inc.
• Shareholders of SiVantage Inc., including Wyatt D. Geist and Nathaniel A. Grawey, are also shareholders of SIMPL Medical, LLC, which sold its SIMPL Business to Tenon Medical, Inc.
• Wyatt D. Geist and Nathaniel A. Grawey, officers of SiVantage, were appointed officers of Tenon Medical and received shares as part of their employment agreements.

Stakeholder Impact

• Shareholders (Tenon Medical): Potential for dilution from new share issuances, but also potential for increased revenue and market share from acquired product lines.
• Shareholders (SiVantage/SIMPL): Received cash, shares, and future royalty/earnout potential from the sale of their businesses.
• Employees (SiVantage/SIMPL): Key personnel (Geist, Grawey) integrated into Tenon Medical management, indicating continuity for some employees.

Next Steps

• Commercialization and sales efforts for SI Products to achieve revenue milestones for earnout shares.
• Commercialization and sales efforts for SIMPL Products to generate royalty revenue.
• Integration of SImmetry and SIMPL businesses into Tenon Medical's operations.
• Potential exercise of outstanding warrants of the Issuer, triggering deferred cash payment.

Key Dates

Recommendation

The acquisition of SiVantage and SIMPL assets represents a strategic expansion for Tenon Medical, potentially enhancing its product portfolio and market position in sacropelvic fixation. The integration of key personnel is a positive. However, the deal involves significant potential share dilution from initial and earnout share issuances, as well as future cash outflows for royalties and deferred payments. While the long-term growth potential is present, the immediate financial implications and integration risks suggest a 'hold' stance until more clarity on financial performance and successful integration emerges.

Keywords

Tenon Medical, SiVantage, SIMPL Medical, Acquisition, Sacropelvic Fixation, Spine Surgery, Medical Devices, Royalty Agreement, Earnout, SEC Filing, Schedule 13D, Common Stock, Corporate Governance